Christine Poon Net Worth

The estimated Net Worth of Christine A Poon is at least $5.31 Million dollars as of 8 May 2019. Ms. Poon owns over 1,558 units of Regeneron Pharmaceuticals stock worth over $4,080,018 and over the last 16 years she sold REGN stock worth over $0. In addition, she makes $1,228,910 as Independent Director at Regeneron Pharmaceuticals.

Ms. Poon REGN stock SEC Form 4 insider trading

Christine has made over 9 trades of the Regeneron Pharmaceuticals stock since 2014, according to the Form 4 filled with the SEC. Most recently she exercised 1,558 units of REGN stock worth $483,728 on 8 May 2019.

The largest trade she’s ever made was exercising 2,006 units of Regeneron Pharmaceuticals stock on 9 May 2017 worth over $622,823. On average, Christine trades about 102 units every 16 days since 2003. As of 8 May 2019 she still owns at least 13,141 units of Regeneron Pharmaceuticals stock.

You can see the complete history of Ms. Poon stock trades at the bottom of the page.

Christine Poon biography

Christine A. Poon is an Independent Director of the Company. Ms. Poon is an Executive-in-Residence in the Department of Management and Human Resources at The Max M. Fisher College of Business at The Ohio State University, where she served as Dean and the John W. Berry, Sr. Chair in Business from 2009 to 2014. Prior to joining Fisher, Ms. Poon spent eight years at Johnson & Johnson, most recently as vice chairman and worldwide chairman of pharmaceuticals. At Johnson & Johnson, she served on the company’s board of directors and executive committee and was responsible for managing the pharmaceutical businesses of the company. Prior to joining Johnson & Johnson, Ms. Poon spent 15 years at Bristol-Myers Squibb Company, a global pharmaceutical company, where she held senior leadership positions including president of international medicines and president of medical devices. Ms. Poon serves on the boards of directors of Prudential Financial, Inc. and The Sherwin-Williams Company and the Supervisory Board of Royal Philips Electronics.

What is the salary of Christine Poon?

As the Independent Director of Regeneron Pharmaceuticals, the total compensation of Christine Poon at Regeneron Pharmaceuticals is $1,228,910. There are 9 executives at Regeneron Pharmaceuticals getting paid more, with Leonard Schleifer having the highest compensation of $26,520,600.

How old is Christine Poon?

Christine Poon is 66, she’s been the Independent Director of Regeneron Pharmaceuticals since 2010. There are 5 older and 11 younger executives at Regeneron Pharmaceuticals. The oldest executive at Regeneron Pharmaceuticals, Inc. is P. Roy Vagelos, 89, who is the Chairman of the Board, Director.

What’s Christine Poon’s mailing address?

Christine’s mailing address filed with the SEC is 101 W. PROSPECT AVENUE, , CLEVELAND, OH, 44115.

Insider trading at Regeneron Pharmaceuticals

Over the last 17 years, insiders at Regeneron Pharmaceuticals have traded over $568,652,500 worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth $2,539,854,760 . The most active insider traders include Sanofi, Pharma Ag Novartis, and P Roy Vagelos. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 10 days with the average trade being worth of $18,191,224. The most recent stock trade was executed by Sanofi on 10 September 2019, trading 172,904 units of REGN stock currently worth $48,611,960.

What does Regeneron Pharmaceuticals do?

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

What does Regeneron Pharmaceuticals’s logo look like?

Complete history of Ms. Poon stock trades at Regeneron Pharmaceuticals, Johnson & Johnson, Prudential, and The Sherwin-Williams Co

Regeneron Pharmaceuticals executives and stock owners

Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include:

• Leonard Schleifer, President, Chief Executive Officer, Director
• George Yancopoulos, President and Chief Scientific Officer – Regeneron, Director
• Marion McCourt, Senior Vice President and Head of Commercial
• Robert Landry, Chief Financial Officer, Executive Vice President – Finance
• Neil Stahl, Executive Vice President – Research and Development
• Daniel Van Plew, Executive Vice President, General Manager – Industrial Operations and Product Supply
• P. Roy Vagelos, Chairman of the Board, Director
• Arthur Ryan, Independent Director
• Michael Brown, Independent Director
• George Sing, Independent Director
• Christine Poon, Independent Director
• Huda Zoghbi, Independent Director
• Joseph Goldstein, Independent Director
• Bonnie Bassler, Independent Director
• Marc Tessier-Lavigne, Independent Director
• N. Anthony Coles, Independent Director
• Christopher Fenimore, Vice President, Controller
• Joseph LaRosa, Executive Vice President, General Counsel, Secretary
• Charles A Baker, Director
• Michael S Aberman, SVP Strategy Investor Relation
• Sanofi,
• Robert J Terifay, EVP Commercial
• Alfred G Gilman, Director
• Robert Alexander Ingram, Director
• Eric M Shooter, Director
• Murray A Goldberg, SVP Administration & Asst Secr
• Stuart Kolinski, SVP General Counsel and Secret
• Amerique Du Nord S.N.C. San…,
• Peter Dworkin, VP Investor Relations & Commun
• Randall Rupp, SVP, Manufuring Operations
• Pharma Ag Novartis, 10% owner
• Hans Peter Guler, VP Clinical Programs
• William Roberts, VP Reg Dev & Med Safety
• Peter Powchik, SVP Clinical Development & Reg
• Douglas S Mc Corkle, VP Controller and Asst Treasur